Pharmaceuticals and Healthcare Reports Japan Dyslipidemia Market

Japan Dyslipidemia Market Opportunities and Outlook Report 2023 “. The launch of the proprotein convertase subtilisin/kexin type 9 (PCSK9) biologics and the cholesteryl ester transfer protein (CETP) inhibitors will reshape the sales landscape of the dyslipidemia market moving forward.” Summary Radiant Insights estimates that the total market size for the 8MM in 2013 was $15.4bn, comprised of $11.0bn in branded drug sales (72%) and $4.4bn in generic sales (28%). Radiant Insights expects that the dyslipidemia drug market will grow at a CAGR of 9.4% over the ten year forecast period, resulting in a market value of $37.9bn by 2023, of which 71% will be attributed to branded drug sales ($26.9bn) and 29% to generic drug sales ($11.0bn). The current dyslipidemia market is dominated by the statins, the revolutionary drugs that reduce low-density lipoprotein cholesterol (LDL-C) and that have been proven to reduce the risk of cardiovascular events such as heart attack and stroke. Other major lipid-modulating drugs, such as Zetia (ezetimibe), the fibrates, bile acid sequestrants, omega-3 fish oil agents, and rare-disease therapies comprise the remainder of the current dyslipidemia space. The launch of the proprotein convertase subtilisin/kexin type 9 (PCSK9) biologics and the cholesteryl ester transfer protein (CETP) inhibitors will reshape the sales landscape of the dyslipidemia market moving forward. Complete Report Available @ http://www.radiantinsights.com/research/dyslipidemia- japan-drug-forecast-and-market-analysis-to-2023 In the 2013 base year, the only dyslipidemia drugs included in this forecast that were available in Japan were the statins, ezetimibe, and the omega-3 fish oil agents. Of these, the statins contributed Follow Us: